Norges Bank Dynavax Technologies Corp Transaction History

Norges Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$10.73 - $12.58 $2.54 Million - $2.97 Million	236,400 New	236,400 $2.65 Million
Q1 2022 May 12, 2023	BUY	$9.75 - $14.44 $7.31 Million - $10.8 Million	750,000 New	750,000 $8.13 Million
Q1 2022 May 09, 2022	SELL	$9.75 - $14.44 $7.31 Million - $10.8 Million	-750,000 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$13.17 - $20.94 $9.88 Million - $15.7 Million	750,000 New	750,000 $10.6 Million
Q3 2021 Nov 14, 2022	BUY	$9.16 - $19.83 $4.01 Million - $8.69 Million	438,300 New	438,300 $8.42 Million

275

130M

451K

203K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.61B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.